Stevanato Group S.p.A. (NYSE:STVN) Receives Consensus Rating of “Buy” from Analysts

Shares of Stevanato Group S.p.A. (NYSE:STVN) have received an average rating of “Buy” from the six research firms that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and two have given a strong buy recommendation to the company.

Several brokerages have weighed in on STVN. TD Cowen upgraded Stevanato Group to a “strong-buy” rating in a research note on Wednesday, June 17th. Weiss Ratings raised Stevanato Group from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 16th. Finally, Wolfe Research started coverage on shares of Stevanato Group in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $21.00 price objective on the stock.

Stevanato Group Stock Down 1.8%

Stevanato Group stock opened at €21.13 on Wednesday. The company has a market capitalization of $6.40 billion, a P/E ratio of 37.73, a PEG ratio of 1.80 and a beta of 0.77. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.08 and a current ratio of 1.61. Stevanato Group has a fifty-two week low of €12.89 and a fifty-two week high of €28.00. The stock has a 50-day simple moving average of €19.04 and a 200-day simple moving average of €17.07.

Insider Buying and Selling

In other news, Director William J. Federici sold 1,493 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of €17.09, for a total value of €25,515.37. Following the completion of the sale, the director owned 26,991 shares in the company, valued at approximately €461,276.19. This trade represents a 5.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Karen Flynn sold 1,493 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of €17.09, for a total transaction of €25,515.37. Following the transaction, the director owned 5,757 shares in the company, valued at approximately €98,387.13. This trade represents a 20.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 14,249 shares of company stock worth $268,346. 0.70% of the stock is currently owned by insiders.

Institutional Trading of Stevanato Group

A number of institutional investors have recently added to or reduced their stakes in the stock. State of Wyoming raised its position in shares of Stevanato Group by 39,216.7% during the 2nd quarter. State of Wyoming now owns 2,359 shares of the company’s stock worth $58,000 after purchasing an additional 2,353 shares during the last quarter. GW&K Investment Management LLC lifted its position in Stevanato Group by 76.2% during the fourth quarter. GW&K Investment Management LLC now owns 2,440 shares of the company’s stock worth $49,000 after buying an additional 1,055 shares during the period. Quantbot Technologies LP purchased a new stake in Stevanato Group in the 3rd quarter valued at about $68,000. Fifth Third Bancorp increased its holdings in shares of Stevanato Group by 22.6% during the 1st quarter. Fifth Third Bancorp now owns 4,196 shares of the company’s stock worth $58,000 after buying an additional 773 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its position in shares of Stevanato Group by 1,268.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,585 shares of the company’s stock worth $112,000 after buying an additional 4,250 shares during the period.

Stevanato Group Company Profile

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.